



Sheet 1 of 10

Form PTO-1449 Modified		Docket No. 08321-0152 CT1	Serial No. 10/656,895
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Scott A. Waldman et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date 09/05/2003	Group 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
SR	AA	Adams, R.D., "Anxiety, Depression, Asthenia, and Personality Disorders" in <i>Harrison's Principles of Internal Medicine</i> , McGraw-Hill Book Co., N.Y., 1983, p. 68	
	AB	Alexander et al., "Oncogene alterations in rat colon tumors induced by N-methyl-N-nitrosourea", <i>Am. J. Med. Sci.</i> , 1992, 303(1), 16-24	
	AC	Beck-Sickinger et al., "Neuropeptide Y: identification of the binding site", <i>Int. J. Peptide Protein Res.</i> , 1990, 36, 522-530	
	AD	Berd et al., "Induction of Cell-mediated Immunity to Autologous Melanoma Cells and Regression of Metastases after Treatment with a Melanoma Cell Vaccine Preceded by Cyclophosphamide", <i>Cancer Res.</i> , 1986, 46, 2572-2577	
	AE	Berd et al., "Immunization with Haptenized, Autologous Tumor Cells Induces Inflammation of Human Melanoma Metastases", <i>Cancer Res.</i> , 1991, 51, 2731-2734	
	AF	Blond-Elguindi et al., "Affinity Panning of a Library of Peptides Displayed on Bacteriophages Reveals the Binding Specificity of BiP", <i>Cell</i> , 1993, 75, 717-728	
	AG	Bold et al., "Experimental gene therapy of human colon cancer", <i>Surgery</i> , 1994, 116(2), 189-196	
	AH	Ciardiello et al., "Inhibition of CRIPTO expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides", <i>Oncogene</i> , 1994, 9(1), 291-298	
	AI	Collins et al., "c-myc antisense oligonucleotides inhibit the colony-forming capacity of Colo 320 colonic carcinoma cells", <i>J. Clin. Invest.</i> , 1992, 89(5), 1523-1527	
✓	AJ	Cooney et al., "Site-Specific Oligonucleotide Binding Represses Transcription of the Human c-myc Gene in Vitro", <i>Science</i> , 1988, 241, 456-459	
EXAMINER		DATE CONSIDERED 2/8/07	

Form PTO-1449 Modified		Docket No. 08321-0152 CT1	Serial No. 10/656,895
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Scott A. Waldman et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date 09/05/2003	Group 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
SP	AK	Coperhave et al., "The Digestive System", <i>Bailey's Textbook of Histology</i> , 16th Edition, Williams and Wilkens, Baltimore, MD, 1975, pg. 404 9	
	AL	Cull et al., "Screening for receptor ligands using large libraries of peptides linked to the C terminus of the <i>lac</i> repressor", <i>Proc. Natl. Acad. Sci. USA</i> , 1992, 89, 1865-1869	
	AM	Francis et al., Peptide Vaccines Based on Enhanced Immunogenicity of Peptide Epitopes Presented with T-Cell Determinants or Hepatitis B Core Protein", <i>Methods in Enzymol.</i> , 1989, 178, 659-676	
	AN	Gallop et al., "Applications of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries", <i>J. Med. Chem.</i> , 1994, 37(9), 1233-1251	
	AO	Gordon et al., "Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions", <i>J. Med. Chem.</i> , 1994, 37(10), 1385-1401	
	AP	Hammer et al., "Promiscuous and Allele-Specific Anchors in HLA-DR-Binding Peptides", <i>Cell</i> , 1993, 74, 197-203	
	AQ	Haralambidis et al., "The Solid Phase Synthesis of Oligonucleotides Containing a 3'-Peptide Moiety", <i>Tetra. Letts.</i> , 1987, 28(43), 5199-5202	
	AR	Helen et al., "Specific regulation of gene expression by antisense, sense, and antigene nucleic acids", <i>Biochem. Biophys. Acta</i> , 1990, 1049, 99-125	
	AS	Kniazhev et al., "Comprehensive Characteristics of Alterations of HER-2/ERBB-2, HER-1/ERBB-1, HRAS-1, and C-MYC Oncogenes, and of p53 and RBI Antioncogenes, and also of Deletions of Loci of Chromosome 17 in Colorectal Carcinomas", <i>Mol. Biol.</i> , 1992, 26(5), 1-15	
7.	AT	Kwok et al., "Calculation of radiation doses for nonuniformly distributed β and γ radionuclides in soft tissue", <i>Med. Phys.</i> , 1985, 12(4), 405-412	
EXAMINER		DATE CONSIDERED 2/8/07	

Form PTO-1449 Modified		Docket No. 08321-0152 CT1	Serial No. 10/656,895
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Scott A. Waldman et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date 09/05/2003	Group 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
SR	AV	Magerstadt, M., <i>Antibody Conjugates and Malignant Disease</i> , CRC Press, Boca Raton, USA, 1991, 110-152	
	AW	Melani et al., "Inhibition of proliferation by <i>c-myb</i> antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express <i>c-myb</i> ", <i>Cancer Res.</i> , 1991, 51(11), 2897-2901	
	AX	Miller et al., "The Induction of Hapten-Specific T Cell Tolerance by Using Hapten-Modified Lymphoid Cells", <i>J. Immunol.</i> , 1976, 117(5:1), 1519-1526	
	AY	Nielsen et al., "Sequence-specific transcription arrest by peptide nucleic acid bound to the DNA template strand", <i>Gene</i> , 1994, 149, 139-145	
	AZ	Osteresh et al., "Libraries from libraries": Chemical transformation of combinatorial libraries to extend the range and repertoire of chemical diversity", <i>Proc. Natl. Acad. Sci. USA</i> , 1994, 91, 11138-11142	
	BA	Ohlmeyer et al., "Complex synthetic chemical libraries indexed with molecular tags", <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90, 10922-10926	
	BB	Ramsey et al., "Myb expression is higher in malignant human colonic carcinoma and premalignant adenomatous polyps than in normal mucosa", <i>Cell Growth & Different.</i> , 1992, 3(10), 723-730	
	BC	Rodriguez-Alfageme et al., "Suppression of deregulated c-MYC expression in human colon carcinoma cells by chromosome 5 transfer", <i>Proc. Natl. Acad. Sci. USA</i> , 1992, 89(4), 1482-1486	
	BD	Ruggeri et al., "Inhibition of platelet function with synthetic peptides designed to be high-affinity antagonists of fibrinogen binding to platelets", <i>Proc. Natl. Acad. Sci. USA</i> , 1986, 83, 5708-5712	
✓	BE	Sad et al., "Bypass of carrier-induced epitope-specific suppression using a T-helper epitope", <i>Immunology</i> , 1992, 76, 599-603	
EXAMINER		DATE CONSIDERED 2/8/07	

Form PTO-1449 Modified		Docket No. 08321-0152 CT1	Serial No. 10/656,895
List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Applicant Scott-A. Waldman et al.	
		Filing Date 09/05/2003	Group 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
52	BF	de Sauvage et al., "Primary Structure and Functional Expression of the Human Receptor for <i>Escherichia coli</i> Heat-stable Enterotoxin", <i>J. Biol. Chem.</i> , 1991, 266(27), 17912-17918	
	BG	Sepetov et al., "Library of libraries: Approach to synthetic combinatorial library design and screening of "pharmacophore" motifs", <i>Proc. Natl. Acad. Sci. USA</i> , 1995, 92, 5426-5430	
	BH	Sizeland et al., "Antisense transforming growth factor alpha oligonucleotides inhibit autocrine stimulated proliferation of a colon carcinoma cell line", <i>Mol. Biol. Cell</i> , 1992, 3(11), 1235-1243	
	BI	Smith et al., "A ribonuclease S-peptide antagonist discovered with a bacteriophage display library", <i>Gene</i> , 1993, 128, 37-42	
	BJ	Takekawa et al., "Chromosomal localization of the protein tyrosine phosphatase G1 gene and characterization of the aberrant transcripts in human colon cancer cells", <i>FEBS Letts.</i> , 1994, 339(3), 222-228	
	BK	Tanaka et al., "Suppression of tumorigenicity in human colon carcinoma cells by introduction of normal chromosome 1p36 region", <i>Oncogene</i> , 1993, 8(8), 2253-2258	
	BL	Toribara et al., "Screening for colorectal cancer", <i>New Eng. J. Med.</i> , 1995, 332(13), 861-867	
	BM	Ullrich et al., "Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity", <i>EMBO J.</i> , 1986, 5(10), 2503-2512	
	BN	Waldman et al., "Immunoaffinity Purification of Soluble Guanylyl Cyclase", <i>Methods in Enzymol.</i> , 1991, 195, 391-396	
X	BO	Wang et al., "Application of the Multipin Peptide Synthesis Technique for Peptide Receptor Binding Studies: Substance P as a Model System", <i>Bioorg. Med. Chem. Lett.</i> , 1993, 3(3), 447-450	
EXAMINER		DATE CONSIDERED 2/8/07	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. 08321-0152 CT1	Serial No. 10/656,895
		Applicant Scott A. Waldman et al.	
		Filing Date 09/05/2003	Group 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
SR	BP	Wessels et al., "Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies", <i>Med. Phys.</i> , 1984, 11(5), 638-645	
	BQ	Wide, "Solid Phase Antigen-Antibody Systems", <i>Radioimmune Assay Method</i> , Kirkham (ed.), E. & S. Livingstone, Edinburgh, 1970, 405-413	
	BR	Wu et al., "Evidence for ed gene delivery to Hep G2 hepatoma cells in vitro", <i>Biochem.</i> , 1988, 27, 887-892	
	BS	Yokozaki et al., "An antisense oligodeoxynucleotide that depletes RI alpha subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells", <i>Cancer Res.</i> , 1993, 53(4), 868-872	
	BT	Zuckermann et al., "Discovery of Nanomolar Ligands for 7-Transmembrane G-Protein-Coupled Receptors from a Diverse N-(Substituted)glycine Peptoid Library", <i>J. Med. Chem.</i> , 1994, 37, 2678-2685	
	BU	Almenoff, et al., "Ligand-based Histochemical Localization and Capture of Cells Expressing Heat-Stable Enterotoxin Receptors", <i>Mol. Microbiol.</i> , 1993, 8, 865-873	
	BV	Chelly, J. et al., "Illegitimate transcription: Transcription of any gene in any cell type", <i>Proc. Natl. Acad. Sci. USA</i> , 1989, 86, 2617-2621	
	BW	Chelly, J. et al., "Illegitimate Transcription: Application to the Analysis of Truncated Transcripts of the Dystrophin Gene in Nonmuscle Cultured Cells from Duchenne and Becker Patients", <i>J. Clin. Invest.</i> , 1991, 88(4), 1161-1166	
	BX	Cohen, M., et al., "Receptors for <i>Escherichia coli</i> Heat Stable Enterotoxin in Human Intestine and in a Human Intestinal Cell Line (Caco-2)", <i>J. Cellular Physiol.</i> , 1993, 156, 138-144	
	BY	Cooper, D.N. et al., "Ectopic (Illegitimate) Transcription: New Possibilities for the Analysis and Diagnosis of Human Genetic Disease", <i>Ann. Med.</i> , 1994, 26(1), 9-14	
	BZ	de Sauvage, F., et al., "Primary Structure and Functional Expression of the Human Receptor for <i>Escherichia coli</i> Heat-stable Enterotoxin", <i>J. Biol. Chem.</i> , 1991, 266, 17912-17918	
✓	CA	Drewett, J. et al., "The Family of Guanylyl Cyclase Receptors and Their Ligands", <i>Endocrine Reviews</i> , 1994, 15(2), 135-162	
EXAMINER 1		DATE CONSIDERED 2/8/07	

Form PTO-1449 Modified		Docket No. 08321-0152 CT1	Serial No. 10/656,895
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Scott A. Waldman et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date 09/05/2003	Group 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
SR	CB	Forte, L., et al., "Receptors and cGMP Signaling Mechanism for E. Coli Enterotoxin in Opossum Kidney", <i>Am. J. Physiol.</i> , 1988, 255 (5 Pt. 2), F1040-F1046	
	CC	Forte, L., et al., " <i>Escherichia coli</i> Enterotoxin Receptors: Localization in Opossum Kidney, Intestine, and Testis", <i>Am. J. Physiol.</i> , 1989, 257 (Pt. 2), F874-881	
	CD	Guarino, A., et al., "T ⁸⁴ Cell Receptor Binding and Guanyl Cyclase Activation by <i>Escherichia coli</i> Heat-Stable Toxin", <i>Am. J. Physiol.</i> , 253 (Gastrointest. Liver Physiol. 16): G775-780, 1987	
	CE	Guerrant, R., et al., "Activation of Intestinal Guanylate Cyclase by Heat-Stable Enterotoxin of <i>Escherichia coli</i> : Studies of tissue Specificity, Potential Receptors, and Intermediates", <i>J. Infect. Dis.</i> , 1980, 142(2), 220-228	
	CF	Hakki, et al., "Solubilization and Characterization of Functionally Coupled <i>Escherichia coli</i> Heat-Stable Toxin Receptors and Particulate Guanylate Cyclase Associated with the Cytoskeleton Compartment of Intestinal Membranes", <i>Int. J. Biochem.</i> , 1993, 25, 557-566	
	CG	Hardingham, J.E., et al., "Immunobead-PCR: A Technique for the Detection of Circulating Tumor Cells Using Immunomagnetic Beads and the Polymerase Chain Reaction", <i>Cancer Research</i> , 1993, 53, 3455-3458	
	CH	Hugues, et al., "Identification and Characterization of a New Family of High-Affinity Receptors for <i>Escherichia coli</i> Heat-Stable Enterotoxin in Rat Intestinal Membranes", <i>Biochemistry</i> , 1991, 30, 10738-10745	
	CI	Kaplan, J.C. et al., "Illegitimate transcription: its use in the study of inherited disease", <i>Human Mutation</i> , 1992, 1(5), 357-360 (Abstract only)	
	CJ	Negrier, C. et al., "Illegitimate transcription: its use for studying genetic abnormalities in lymphoblastoid cells from patients with Glanzmann thrombasthenia", <i>British J. Haematology</i> , 1998, 100(1), 33-39	
	CK	Thompson, M.R., " <i>Escherichia coli</i> Heat-Stable Enterotoxins and Their Receptors", <i>Pathol. Immunopathol. Res.</i> , 1987, 6, 103-116	
✓	CL	Zippelius, A. et al., "Limitations of Reverse-Transcriptase Polymerase Chain Reaction Analyses for Detection of Micrometastatic Epithelial Cancer Cells in Bone Marrow", <i>J. Clin. Oncology</i> , 1997, 15(7), 2701-2708	
EXAMINER 1		DATE CONSIDERED 2/8/07	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. 08321-0152 CT1		Serial No. 10/656,895	
				Applicant Scott A. Waldman et al.			
				Filing Date 09/05/2003		Group 1614	
U. S. PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
SR	CM	4,022,878	05/10/77	Gross	424	1.5	
	CN	4,329,281	05/11/82	Christenson et al.	260	112 B	
	CO	4,526,716	07/02/85	Stevens	260	112.5 R	
	CP	4,584,268	04/22/86	Ceriani et al.	436	504	
	CQ	4,601,896	07/22/86	Nugent	424	36	
	CR	4,683,195	07/28/87	Mullis et al.	435	6	
	CS	4,683,202	07/28/87	Mullis	435	91	
	CT	4,729,893	03/08/88	Letcher et al.	424	98	
	CU	4,736,866	04/12/88	Leder et al.	800	1	
	CV	4,849,227	07/18/89	Cho	424	498	
	CW	4,873,191	10/10/89	Wagner et al.	435	172.3	
	CX	4,945,050	07/31/90	Sanford et al.	435	172.1	
	CY	4,963,263	10/16/90	Kauvar	210	635	
	CZ	4,965,188	10/23/90	Mullis et al.	435	6	
	DA	5,017,487	05/21/91	Stunnenberg et al.	435	172.3	
	DB	5,037,645	08/06/91	Strahilevitz	424	85.8	
	DC	5,075,216	12/24/91	Innis et al.	435	6	
	DD	5,112,606	05/12/92	Shiosaka et al.	530	389.2	
Y	DE	5,133,866	07/28/92	Kauvar	210	635	
EXAMINER 1				DATE CONSIDERED 2/8/07			

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. 08321-0152 CT1		Serial No. 10/656,895	
				Applicant Scott A. Waldman et al.			
				Filing Date 09/05/2003		Group 1614	
U. S. PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
SR	DF	5,143,854	09/01/92	Pirrung et al.	436	518	
	DG	5,160,723	11/03/92	Welt, et al.	424	1.1	
	DH	5,217,869	06/08/93	Kauvar	435	7.9	
	DI	5,221,736	06/22/93	Coolidge et al.	536	25.31	
	DJ	5,223,409	06/29/93	Ladner et al.	435	69.7	
	DK	5,237,051	08/17/93	Garbers et al.	530	350	
	DL	5,252,743	10/12/93	Barrett et al.	548	303.7	
	DM	5,270,170	12/14/93	Schatz et al.	435	7.37	
	DN	5,271,961	12/21/93	Mathiowitz et al.	427	213.31	
	DO	5,288,514	02/22/94	Ellman	427	2	
	DP	5,324,483	06/28/94	Cody et al.	422	131	
	DQ	5,330,892	07/19/94	Vogelstein et al.	435	6	
	DR	5,338,665	08/16/94	Schatz et al.	435	6	
	DS	5,340,474	08/23/94	Kauvar	210	198.2	
	DT	5,350,741	09/27/94	Takada	514	3	
	DU	5,352,775	10/04/94	Albertsen et al.	536	23.1	
	DV	5,366,862	11/22/94	Venton et al.	435	7.1	
	DW	5,384,261	01/24/95	Winkler et al.	436	518	
	DX	5,395,750	03/07/95	Dillon et al.	435	5	
Y	DY	5,399,347	03/21/95	Trentham et al.	424	184.1	
EXAMINER 1				DATE CONSIDERED 2/8/07			

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. 08321-0152 CT1		Serial No. 10/656,895	
				Applicant Scott A. Waldman et al.			
				Filing Date 09/05/2003		Group 1614	
U. S. PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
SR	DZ	5,405,783	04/11/95	Pirrung et al.	436	518	
	EA	5,412,087	05/02/95	McGall et al.	536	24.3	
	EB	5,420,328	05/30/95	Campbell	558	110	
	EC	5,424,186	06/13/95	Fodor et al.	435	6	
	ED	5,430,138	07/04/95	Urdea et al.	536	26.8	
	EE	5,437,977	08/01/95	Segev	435	6	
	EF	5,597,909	01/28/97	Urdea et al.	536	24.3	
	EG	5,731,159	03/24/98	Waldman	435	7.23	
	EH	5,518,888	05/21/96	Waldman	435	7.23	
	EI	5,601,990	02/11/97	Waldman	435	7.23	
	EJ	5,928,873	07/27/99	Waldman	435	6	
	EK	5,962,220	10/05/99	Waldman	435	6	
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Country	Translation YES NO		
SR	EL	WO 95/11694	05/04/95	PCT			
	EM	WO 97/42220	11/13/97	PCT			
	EN	WO 97/42506	11/13/97	PCT			
EXAMINER				DATE CONSIDERED 2/8/07			

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. 08321-0152 CT1	Serial No. 10/656,895
		Applicant Scott A. Waldman et al.	
		Filing Date 09/05/2003	Group 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
SR ↓	119	Carrithers, S.L. Ph.D., et al. " <i>Escherichia Coli</i> Heat -Stable Enterotoxin Receptors: A Novel Marker for Colorectal Tumors", <i>Diseases of the Colon and Rectum</i> , 1996, 39(2), 171-181	
	120	Rousset, B. et al., "Bacterial Enterotoxin Receptors", <i>Veterinary Research</i> , 2000, 31(4), 413-435 (Abstract Provided)	
	121	S. Schulz, Ph.D., "A Splice Variant of the Heat-Stable Enterotoxin Receptor", <i>Clinical Pharmacology & Therapeutics</i> , 1998, 63(2), 226	
	122	de Sauvage et al. (Accession #M73489, 1991)	
	123	Singh et al. (Accession #S57551, 1991)	
	124	Skolnick J, et al. TRENDS BIOTECH 2000; 18(1): 34-39	
	125	Database GENBANK, Accession No. AC010106, 19 September 2000	
	126	Database GENBANK, Accession No. AL359386, 20 January 2001	
EXAMINER		DATE CONSIDERED	
1		2/8/07	

MAY 03 2008

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute Patent 9,98B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number

10/656,895

Filing Date

September 5, 2003

First Named Inventor

Scott A. Waldman

Art Unit

1643

Examiner Name

Rawlings, Stephen L.

Attorney Docket Number

TJU0007-103

NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08A (07-05)

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 3

Complete If Known

Application Number	10/656,895
Filing Date	September 5, 2003
First Named Inventor	Scott A. Waldman
Art Unit	1643
Examiner Name	Stephen L. Rawlings
Attorney Docket Number	TJU0007-103

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
S R	10	Carrithers, et al., "Escherichia Coli Heat-Stable Toxin Receptors in Human Colonic Tumors", Gastroenterology, 1994, 107, 1653-1661	
	11	Carrithers, et al., "Guanylyl Cyclase C Is A Selective Marker For Metastatic Colorectal Tumors In Human Extraintestinal Tissues", Proc. Natl. Acad. Sci USA, 1996, 93, 14827-14832	
	12	Ohyama, et al., "Cloning and Characterization of Two Forms of C-Type Natriuretic Peptide Receptor in Rat Brain", Biochem. & Biophys. Res. Comm., 1992, 183, 743-749	
	13	Singh, et al., "Isolation and Expression of a Guanylate Cyclase-Coupled Heat Stable Enterotoxin Receptor cDNA from a Human Colonic Cell Line", Biochem. & Biophys. Res. Commun., 1991, 179, 1455-1463	
	14	Tallerico-Melnik, et al., "A Novel Guanylyl Cyclase-A Isoform: Rat GC-A1 Identification and mRNA Localization to Renal Papilla and Adrenal", Biochem. & Biophys. Res. Commun., 1995, 209, 930-935	
	15	Bostick PJ, et al., "Limitations Of Specific Reverse-Transcriptase Polymerase Chain Reaction Markers In The Detection Of Metastases In The Lymph Nodes And Blood Of Breast Cancer Patients", J. Clin. Oncol. 1998,16(8): 2632-40	
	16	Critchfield GC, "The Future Of DNA Diagnostics", Disease Markers, 1999, 15, 108-11	
	17	Sidransky D, "Nucleic Acid-Based Methods For The Detection Of Cancer " Science, 1997, 278, 1054-9	
	18	Cagir B, et al., "Guanylyl Cyclase C Messenger RNA Is A Biomarker For Recurrent Stage II Colorectal Cancer " Annals Int Med., 1999, 131(11), 805-12	
	19	Bustin SA, et al., "Detection Of Cytokeratins 19/20 And Guanylyl Cyclase C In Peripheral Blood Of Colorectal Cancer Patients", Br J Cancer, 1999, 79(11-12), 1813-20	
	20	Castells A, et al., "Detection of Colonic Cells In Peripheral Blood Of Colorectal Cancer Patients By Means Of Reverse Transcriptase And Polymerase Chain Reaction ", Br J Cancer, 1998, 78(10), 1368-72	
	21	Park J, et al., "Ectopic Expression Of Guanylyl Cyclase C In Adenocarcinomas Of The Esophagus And Stomach", Cancer Epidemiol Biomarkers Prev., 2002, 11, 739-44	
	22	Fava TA, et al., "Ectopic Expression Of Guanylyl Cyclase C In CD34+ Progenitor Cells In Peripheral Blood", Cancer Epidemiol Biomarkers Prev., 2001, 10(19), 3951-9	
Y	23	Viems FA, et al., "Investigations For A Multi-Marker RT-PCR To Improve Sensitivity Of Disseminated Tumor Cell Detection", Anticancer Res. 2003, 23(1A), 179-88	

Examiner Signature		Date Considered	2/8/07
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Received 18 NPC

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/656,895
		Filing Date	September 5, 2003
		First Named Inventor	Scott A. Waldman
		Art Unit	1643
		Examiner Name	Stephen L. Rawlings
		Attorney Docket Number	TJU0007-103
Sheet	3	of	3

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SR	24	Michalevicz R, et al., "Characterization Of Lympho-Myeloid-Erythroid-Megakaryocytic Stem Cells In Peripheral Blood Of Hairy Cell Leukemia Patients", Leuk. Res., 1989, 13(10), 915-20	
	25	Silvestri F., et al., "The CD34 Hemopoietic Progenitor Cell Associated Antigen: Biology And Clinical Applications", Haematologica, 1992, 77(3), 285-73	
	26	Ward AM, "Tumour Markers", Develop Oncol., 1985, 21, 91-108	
	27	Tockman MS, et al., "Considerations In Bringing A Cancer Biomarker To Clinical Application", Cancer Res., 1992, 52, 2711s-2718s	
	28	Boehringer Mannheim Biochemicals, 1994 Catalog (No. 1034 731/1006 924), page 93	
	29	Houdebine LM, "Production Of Pharmaceutical Proteins From Transgenic Animals", J Biotechnol., 1994, 34(3), 269-87	
	30	Verma IM, et al., "Gene Therapy -- Promises, Problems And Prospects", Nature, 1997, 389(6648), 239-42	
	31	Patterson AP, Memorandum (January 14, 2003), page 3	
	32	Pandha HS, et al., "Oncological Applications Of Gene Therapy", Cur Gene Ther., 2002, 2, 111-33	
✓	33	Amalfitano A, et al., "Separating Fact From Fiction: Assessing The Potential Of Modified Adenovirus Vectors For Use In Human Gene Therapy", Cur Gene Ther. 2002, 2, 111-33	

Examiner Signature		Date Considered	2/8/07
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.